secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002225
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

TransCode stockholders approve reverse stock split of RNAZ common stock at ratio between 1:10 and 1:40
--------------------------------------------------------------------------------

- Special meeting Jan 8, 2024: 12,472,113 shares voted of 25,097,596 entitled.
- Reverse split approved: 7,081,896 for, 5,348,629 against, 41,588 abstentions.
- Board has discretion to implement the split at a specific ratio and timing.
- Adjournment proposal passed (7,426,024 for) but not needed after reverse split approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924002225/0001104659-24-002225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924002225/tm242383d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer